Trusted Resources: People & Places
Healthcare providers, researchers, and advocates
David Beidler, PhD
Researcher Senior Director, Precision Medicine, Early Clinical Development
Pfizer Inc.
Global Research and Development -
Rare Diseases Research Unit
1 Portland Street
Cambridge, Massachusetts, United States
As the Translational Sciences lead for the phosphodiesterase type 9 inhibitor project, Dr. Beidler contributed to the development, implementation, and analysis of pharmacodynamic biomarkers in the recent phase 1b study in stable sickle cell disease subjects. Dr. Beidler has over 17 years of pharmaceutical industry experience with biomarker/translational pharmacology strategy and clinical operations that span preclinical animal models, natural history/methodology studies, and early (Phase 1/2) clinical trials. Dr. Beidler has also served as the research project team leader and in vivo pharmacology lead on several pain/inflammation project teams that delivered multiple candidate compounds to the clinic.
Representative Publications:
Safety and Tolerability of PF-04447943 across a Clinical Trial Program Including 277 Patients
Related Content
-
Elyse Mandell, MSN, RNCSElyse Mandell is the Nurse Director and ...
-
Matthew Karafin, MD, MSMatthew Karafin, MD, MS is the associate...
-
Home Oxygen Therapy for Children: An Official American Thoracic Society Clinical Practice GuidelineBackground: Home oxygen therapy is ofte...
-
Healthcare Providers and Sickle Cell DiseaseSickle cell disease (SCD) is a group of ...
-
Children’s Hospital of PittsburghChildren’s Hospital of Pittsburgh of U...
-
4 Transition Stages of Sickle Cell Disease and Tips for Each Stagehttps://www.onescdvoice.com/wp-content/u...
-
Colorado Sickle Cell Research and Treatment CenterColorado Sickle Cell Treatment and Resea...
+myBinder